feed,title,long_url,short_url
Benzinga,Kymera Therapeutics' KT-413 Shows Encouraging Preclinical Anti-Cancer Activity,https://benzinga.com/general/biotech/21/06/21644469/kymera-therapeutics-kt-413-shows-encouraging-preclinical-anti-cancer-activity,https://j.mp/3gLJsKV
